Plasma zinc status and hyperinflammatory syndrome in hospitalized COVID-19 patients: an observational study
Verschelden et al.,
Plasma zinc status and hyperinflammatory syndrome in hospitalized COVID-19 patients: an observational study,
medRxiv, doi:10.1101/2021.06.09.21258271 (Preprint)
Prospective study of 139 hospitalized COVID-19 patients, showing 96% had zinc deficiency. Higher zinc levels were associated with a shorter length of hospitalization. Mortality and ventilation was lower with higher zinc levels, but not reaching statistical significance.
Verschelden et al., 12 Jun 2021, preprint, 8 authors.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.06.09.21258271; this version posted July 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
1
2
3
Title
Plasma zinc status and hyperinflammatory syndrome in hospitalized
COVID-19 patients: an observational study
4
5
6
7
Authors: Gil Verschelden , Maxim Noeparast , Maryam Noparast , Maïlis
1*
2,3*
4
Lauwers , Charlotte Michel , Frédéric Cotton , Cleo Goyvaerts , Maya Hites .
5
6
7
7
1
* Shared first authors
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
1. Clinic of Infectious Diseases, Cliniques Universitaires de Bruxelles (CUB),
Erasme Hospital, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium
2. Institute of Molecular Oncology, Member of the German Center for Lung
Research (DZL), Philipps University, 35043 Marburg, Germany
3. Fonds Wetenschappelijk Onderzoek (FWO) – Vlaanderen
4. Department of Urologic Sciences, University of British Columbia, Vancouver,
BC, Canada.
5. Department of Clinical Chemistry, Laboratoire Hospitalier Universitaire de
Bruxelles (LHUB-ULB), Université Libre de Bruxelles (ULB), Brussels,
Belgium
6. Department of Microbiology, Laboratoire Hospitalier Universitaire de
Bruxelles (LHUB-ULB), Brussels, Belgium
7. Department of Clinical Chemistry, Laboratoire Hospitalier Universitaire de
Bruxelles (LHUB-ULB), Université Libre de Bruxelles (ULB), Brussels,
Belgium
8. Laboratory for Molecular and Cellular Therapy (LMCT), Vrije Universiteit
Brussel (VUB), 1090 Brussels, Belgium
26
1
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2021.06.09.21258271; this version posted July 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
27
28
Corresponding authors: Gil.Verschelden@erasme.ulb.ac.be,
Maxim.Noeparast@staff.uni-marburg.de, and Maya.Hites@erasme.ulb.ac.be
29
30
31
32
33
Abstract
Deficiency of the element zinc is associated with cytokine releasing syndrome (CRS)
and the related acute respiratory distress syndrome as well as impaired antiviral
response. Similar complications associate with severe SARS-CoV-2.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
We conducted a prospective, single-center, observational study in a tertiary
university hospital (CUB-Hopital Erasme, Brussels) to address the zinc status, the
association between the plasma zinc concentration, development of CRS, and the
clinical outcomes in PCR-confirmed and hospitalized COVID-19 patients.
One hundred and thirty-nine eligible patients were included between May 2020 and
November 2020 (median age of 65 years [IQR, 54 to 77]).
Our cohort's mean plasma zinc concentration was 56.2 µg/dL (standard deviation
[SD], 14.8) compared to 75.7 µg/dL (SD = 18.9 µg/dL) in the retrospective nonCOVID-19 control group (N = 1513; P <.001). Markedly, the absolute majority of
patients (96%) were zinc deficient (<80 µg/dL).
The mean zinc concentration was lower in patients with CRS compared to..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit